No licensed vaccine against scarlet fever exists, and none is expected to reach the market in the near future. The disease is caused by Group A Streptococcus (often abbreviated GAS or its formal name, Streptococcus pyogenes), a bacterium that has frustrated vaccine developers for over a century. The reasons span biology, immunology, and safety: the germ is extraordinarily diverse, parts of it look dangerously similar to human tissue, and the animal models researchers rely on do not faithfully replicate what happens in people. Despite all of that, the need for a vaccine has arguably never been greater, because scarlet fever has been making a global comeback and antibiotic resistance in the pathogen is growing.
What Makes Group A Strep So Difficult to Vaccinate Against
Most successful bacterial vaccines work by training the immune system to recognize one or two surface molecules that are consistent across nearly all strains. Group A Strep does not cooperate. Its primary surface protein, called M protein, is the main target the immune system uses to fight the bacterium, but it comes in more than 200 distinct types defined by differences in the part of the molecule that antibodies latch onto.1PubMed Central. Design of broadly cross-reactive M protein-based group A streptococcal vaccines An immune response trained against one M type may do little against another. On top of that, different M types circulate in different parts of the world, so a vaccine built around the strains common in North America could leave children in sub-Saharan Africa or Southeast Asia largely unprotected.
Beyond the M protein, the bacterium deploys an unusually large arsenal of secreted toxins and enzymes. These include superantigens, which hijack the immune system by activating enormous numbers of T cells at once, triggering a flood of inflammatory signals far out of proportion to the actual infection.2PubMed Central. Proinflammatory synergy between protease and superantigen streptococcal pyogenic exotoxins Other toxins punch holes in cell membranes or chew through tissue. The collective toxin toolkit of GAS is rivaled by few other bacterial pathogens, giving it multiple ways to cause disease and making it harder to neutralize with a single vaccine strategy.3PubMed Central. Toxins and Superantigens of Group A Streptococci
The Autoimmunity Problem
Even if researchers could build a vaccine that generated strong antibodies against M protein, there is a well-documented safety concern: parts of M protein structurally resemble proteins found in the human heart, brain, and joints. This resemblance, known as molecular mimicry, is the driving force behind rheumatic fever and rheumatic heart disease, two serious complications that can follow an untreated strep throat infection. The streptococcal M protein and group A carbohydrate share structural features with cardiac myosin, and antibodies raised against the bacterium can cross-react with heart tissue.4PubMed. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease In broader terms, the sharing of epitopes between the bacterium and the host leads to autoantibodies that can attack the body’s own tissues.5PubMed Central. Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae
This creates a paradox for vaccine designers. The very molecule you most want to target is the one most likely to trigger an autoimmune reaction if the vaccine is not carefully engineered. In the mid-twentieth century, early vaccine trials using whole or crude M protein preparations were linked to cases of rheumatic fever in some recipients, and the resulting regulatory caution has cast a long shadow over the field. For decades, the U.S. Food and Drug Administration maintained extra scrutiny over GAS vaccine proposals, and the memory of those early harms continues to shape how cautiously researchers approach clinical trials today.
A Century of Trying
The quest for a scarlet fever vaccine is not new. In 1923, researchers reported a skin test for susceptibility to scarlet fever along with early attempts at preventive immunization using scarlet fever toxin.6JAMA. Results With the Skin Test for Susceptibility to Scarlet Fever: Preventive Immunization With Scarlet Fever Toxin The approach involved injecting patients with diluted toxin produced by the bacterium, and it showed some promise in reducing cases. But those early toxin-based vaccines were crude by modern standards and fell out of use as antibiotics, particularly penicillin, arrived in the 1940s and made strep infections treatable and far less deadly.
The availability of cheap, effective antibiotics took much of the urgency out of vaccine development. Scarlet fever went from a feared killer of children to a manageable illness that could usually be cleared with a course of penicillin. For decades, pharmaceutical companies and funding agencies saw little commercial incentive to invest in a vaccine for a disease that antibiotics could handle. That calculation is now shifting, but the decades-long gap in serious investment left the field far behind where vaccines for other childhood infections progressed.
Why Scarlet Fever Is Coming Back
Starting around 2011, several countries reported sharp increases in scarlet fever cases after decades of decline. England recorded pronounced upsurges over an eight-year period before the COVID-19 pandemic temporarily suppressed transmission.7Emerging Infectious Diseases. Emerging Invasive Group A Streptococcus M1UK Lineage Detected by Allele-Specific PCR, England, 2020 Parts of East Asia, including mainland China and Hong Kong, experienced even larger epidemics. In England, both scarlet fever and more dangerous invasive GAS infections were linked to the emergence of a new sublineage called M1UK, which produces higher levels of the superantigen SpeA than the previously dominant global M1 strain.
In Northeast Asia, the picture was more complex. Detailed genetic analyses showed that the scarlet fever surge was not driven by a single clone but by multiple strains that had independently acquired new toxin-carrying genetic elements, particularly virus-like particles called prophages that carry genes for superantigens and DNA-degrading enzymes.8PubMed Central. Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes In other words, the bacterium is not just sitting still. It is actively acquiring new genetic weaponry through horizontal gene transfer, and these newly armed strains appear to colonize and spread more effectively. This evolutionary dynamism adds another layer of difficulty for vaccine developers: a target that keeps changing is harder to hit.
Modern Vaccine Strategies in the Pipeline
Despite the obstacles, several distinct vaccine approaches are now in various stages of development. They roughly fall into three categories, each with its own advantages and trade-offs.
Multivalent M Protein Vaccines
The most advanced approach takes the M protein problem head-on by including peptide fragments from many different M types in a single vaccine. The idea is to generate antibodies against enough M types to cover the majority of circulating strains. Researchers have identified cross-reactive pairs among M proteins, meaning antibodies raised against one M type can sometimes neutralize a related type as well. One recent design selected 19 M types predicted to cross-react with 37 additional types, which, combined with 13 type-specific peptides, would theoretically provide about 90 percent global coverage.9PubMed Central. Structure-Guided Design of a Broadly Cross-Reactive Multivalent Group A Streptococcal Vaccine
Earlier multivalent formulations have been tested for their ability to kill GAS strains in laboratory assays. One study evaluated a candidate against isolates from Bamako, Mali, and found that antibodies generated by the vaccine could kill bacteria representing about 81 percent of all infections recorded there, including many strains whose M types were not directly included in the vaccine formula.10PubMed Central. Potential coverage of a multivalent M protein-based group A streptococcal vaccine Several multivalent M protein vaccines have moved into early-stage human clinical trials.11PubMed Central. Update on group A streptococcal vaccine development
Conserved Antigen Vaccines
A second strategy sidesteps the M protein entirely. Instead, researchers look for proteins on the bacterial surface that are virtually identical across all GAS strains. Using human antibodies from people who had been naturally exposed to GAS, one research group identified nine protective antigens that showed greater than 97 percent sequence identity across published genomes and roughly 50 clinical isolates tested.12PubMed Central. Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine Because these proteins barely vary from strain to strain, a vaccine based on them could theoretically work worldwide without needing to be reformulated for different regions. The challenge is proving that antibodies against these conserved targets actually prevent infection or disease in people, not just in the lab.
Toxin-Based Vaccines
A third approach targets the toxins that cause scarlet fever’s characteristic rash and systemic inflammation rather than the bacterium itself. One candidate, called VaxiStrep, is a recombinant fusion protein combining detoxified versions of two key exotoxins: SpeA (a superantigen) and SpeB (a protease that damages tissue).13PubMed Central. Group A Streptococcus Vaccine Targeting the Erythrogenic Toxins SpeA and SpeB Is Safe and Immunogenic in Rabbits and Does Not Induce Antibodies Associated with Autoimmunity Animal testing showed it was safe, generated a strong immune response, and did not produce the autoimmune antibodies that have historically worried regulators. The logic here is that even if the vaccine does not prevent GAS colonization of the throat, it could prevent the toxin-mediated disease, including scarlet fever, that follows. A toxin-focused approach may also dodge the autoimmunity problem since the targets are bacterial secretions rather than surface molecules that mimic human proteins.
Some researchers have argued that the best eventual vaccine will likely combine elements of multiple strategies, perhaps pairing selected M protein fragments with conserved antigens or detoxified superantigens, to provide both breadth of strain coverage and protection against the most damaging toxins.14PLoS Pathogens. Streptococcal superantigens and the return of scarlet fever
The Animal Model Gap
One underappreciated reason for the slow pace of GAS vaccine development is that the bacterium is essentially a human-only pathogen. Mice, the workhorse of vaccine research, do not naturally get strep throat or scarlet fever, and their immune systems respond differently to GAS infection than ours do. This means that a vaccine candidate can look highly effective in mice and still fail in people. Translating findings from mouse models to clinical success remains a major challenge, and researchers increasingly acknowledge the need to complement animal studies with laboratory-based functional assays and, where feasible, testing in non-human primates.15npj Vaccines. Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities Non-human primate studies are far more expensive and logistically complex than mouse work, which further slows the pipeline.
Antibiotic Resistance and the Shifting Calculus
For decades, the reliable sensitivity of GAS to penicillin served as a safety net that reduced pressure to develop a vaccine. Penicillin still works against GAS, and so do certain other antibiotics like ceftriaxone and vancomycin. But resistance to other commonly used drugs, particularly macrolides like erythromycin and lincosamides like clindamycin, is growing. A study of scarlet fever GAS isolates from pediatric cases in Shenzhen, China, found that while strains remained sensitive to penicillin, they were highly resistant to erythromycin and clindamycin.16PubMed. Prevalence and identification of antibiotic-resistant scarlet fever group A Streptococcus strains in some paediatric cases at Shenzhen, China This matters because macrolides are the go-to alternative for patients allergic to penicillin, and clindamycin plays a critical role in treating invasive GAS infections where toxin production needs to be shut down quickly.
If resistance spreads further or, in a worst-case scenario, reaches penicillin itself, the consequences would be severe. GAS causes not only scarlet fever but also strep throat, skin infections, and life-threatening invasive diseases like necrotizing fasciitis and streptococcal toxic shock. In low-resource settings where antibiotic access is already inconsistent, untreated strep infections drive some of the highest rates of rheumatic heart disease in the world. A vaccine could be a cost-effective way to reduce disease burden in exactly those populations where treatment is hardest to deliver.17PubMed Central. Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease-streptococcal vaccine development
Clues from Natural Immunity
One reason researchers remain optimistic despite all these hurdles is that the human body does develop meaningful immunity to GAS over time. The rate of acute strep infections, including scarlet fever, peaks in childhood and drops substantially in adulthood. Symptomatic throat infections rise sharply around age four and then gradually decline as the immune system accumulates experience with multiple GAS strains.18PubMed Central. Correlates of immunity to Group A Streptococcus: a pathway to vaccine development The fact that repeated natural exposure eventually confers some protection suggests that a well-designed vaccine could accelerate this process without requiring years of actual infections to build up immunity. The challenge is figuring out exactly which immune responses matter most and replicating them safely with a vaccine.
Diagnosing Scarlet Fever Is Trickier Than You Might Think
While not directly a vaccine issue, one reason scarlet fever persists and sometimes goes underrecognized is that it does not always present the way textbooks describe. A study of 171 cases found that scarlet fever pharyngotonsillitis differs from the classic streptococcal sore throat, and standard clinical scoring systems used to predict strep throat perform poorly for scarlet fever specifically. The rash itself turns out to be the most reliable diagnostic clue, regardless of the patient’s age.19Enfermedades Infecciosas y Microbiología Clínica. Scarlet fever: A not so typical exanthematous pharyngotonsillitis (based on 171 cases) Missed or delayed diagnoses mean delayed antibiotic treatment, which increases the window for complications and for the bacterium to spread. A vaccine that prevented the toxin-mediated rash, or the infection altogether, would eliminate this diagnostic challenge at its root.
How Superantigens Complicate the Picture
Superantigens deserve special attention because they sit at the intersection of scarlet fever’s symptoms and the difficulty of building a vaccine. Unlike a normal bacterial protein that activates a small, targeted slice of the immune system, a superantigen bridges immune cells in a way that activates a massive, non-specific inflammatory response.20PubMed Central. Bacterial pyrogenic exotoxins as superantigens This is what produces the high fever and widespread rash of scarlet fever, and in extreme cases, it can lead to toxic shock and organ failure.
The problem for vaccine designers is that GAS carries multiple superantigen genes, and different strains carry different combinations. Many of these genes ride on prophages, the virus-like mobile genetic elements mentioned earlier, which means a strain can gain or lose superantigen genes over relatively short evolutionary timescales. A vaccine targeting one or two superantigens could be outflanked by a strain carrying a different set. Researchers have proposed that carefully selected, detoxified superantigens might still be valuable components of a multicomponent vaccine, particularly for use during lineage-specific epidemics where the dominant superantigen profile is known.14PLoS Pathogens. Streptococcal superantigens and the return of scarlet fever But as a standalone strategy, targeting superantigens alone cannot provide the global coverage needed for a universal GAS vaccine.
Why Funding and Commercial Interest Have Lagged
The scientific obstacles alone do not fully explain why there is no scarlet fever vaccine. Commercial incentives have been weak for most of the last 80 years. The disease burden of GAS falls disproportionately on children in low- and middle-income countries, populations that are historically underserved by pharmaceutical markets. Rheumatic heart disease alone kills hundreds of thousands of people annually, the vast majority in sub-Saharan Africa, South Asia, and the Pacific Islands, but because those deaths are concentrated in poorer nations, they have not generated the kind of market-driven investment that powered the development of vaccines against HPV or pneumococcal disease. The technical risk is also high: the autoimmunity concerns mean that clinical trials require unusually careful monitoring and large safety datasets, which drives up costs and lengthens timelines.
Recent epidemics in wealthy countries, particularly the post-2011 surges in England and Australia, have helped shift the political landscape. International workshops and funding calls from agencies like the U.S. National Heart, Lung, and Blood Institute have specifically identified GAS vaccine development as a priority for preventing rheumatic fever and rheumatic heart disease.17PubMed Central. Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease-streptococcal vaccine development Whether this translates into sustained funding and commercial partnerships remains to be seen, but the conversation has shifted meaningfully compared to even ten years ago.
How Adjuvants and Formulation Are Evolving
One practical bottleneck has been the limited toolbox for boosting immune responses to GAS antigens. Traditional aluminum-based adjuvants, the immune-stimulating additives mixed into many childhood vaccines, generate a moderate response but may not be strong enough for GAS. Newer vaccine formulations have incorporated universal T-cell epitopes, toll-like receptor agonists, and other adjuvants more potent than aluminum salts, and these have been shown to enhance protective immune responses in animal models.11PubMed Central. Update on group A streptococcal vaccine development Stronger adjuvants could allow vaccines to use smaller amounts of antigen while still generating durable protection, which matters both for manufacturing scalability and for minimizing the risk of triggering the autoimmune responses that have haunted this field. Progress in adjuvant science is not unique to GAS, but GAS vaccine developers stand to benefit disproportionately because the margin between “strong enough to protect” and “strong enough to cause harm” may be narrower here than for most other pathogens.